Lipopolysaccharide regulated protein expression is only partly impaired in monocytes from patients with type I diabetes.
BACKGROUND
Monocytes play an important role in innate immunity and atherosclerosis. A disturbed secretion of cytokines in lipopolysaccharide (LPS) activated monocytes from type 1 diabetes (T1D) patients has been described and may contribute to the impaired inflammatory response in these individuals. In the present study the influence of LPS on five different proteins with a function in immunity and atherosclerosis was analyzed in monocytes from controls and T1D patients.


METHODS
Monocytes were isolated from controls and T1D patients and the LPS-stimulated increase of IL-6, CXCL8, monocyte chemotactic protein 1 (CCL2, MCP-1) and superoxide dismutase (SOD 2), as well as the LPS-mediated decrease of apolipoprotein E (Apo E) in primary human monocytes from controls and T1D patients was determined.


RESULTS
CCL2 and IL-6 secretion in response to LPS was found significantly reduced in monocytes from T1D patients when compared to controls whereas basal CCL2 release was similar in control and T1D cells. In contrast, CXCL8 and apolipoprotein E secretion and SOD 2 expression upon LPS stimulation is similar from T1D and control monocytes.


CONCLUSIONS
These data indicate that LPS-mediated protein expression is only partly disturbed in monocytes from T1D patients. Reduced secretion of IL-6 and CCL2 in activated monocytes of these patients may contribute to an impaired inflammatory response and vascular disease.
Wehrwein
Gabriele
G
Department of Internal Medicine I, University of Regensburg, D-93042 Regensburg, Germany. gwehrwein@yahoo.de
Neumeier
Markus
M
Schäffler
Andreas
A
Kopp
Andrea
A
Weigert
Johanna
J
Abke
Sabine
S
Schölmerich
Jürgen
J
Buechler
Christa
C
D000328:Adult; D001057:Apolipoproteins E / Q000097:blood; D001798:Blood Proteins / Q000378:metabolism*; D016022:Case-Control Studies; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000097:blood; D019743:Chemokines, CXC / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism*; D013482:Superoxide Dismutase / Q000097:blood; D000099156:Superoxide Dismutase 2
D001057:Apolipoproteins E; D001798:Blood Proteins; D018932:Chemokine CCL2; D019743:Chemokines, CXC; D015850:Interleukin-6; D008070:Lipopolysaccharides; D013482:Superoxide Dismutase; D000099156:Superoxide Dismutase 2; C111835:CCL2 protein, human